Elsevier Sponsors Royal Australian Chemical Institute's 2010/11 Organic Division Lectureship Award

The Lectureship provides the opportunity for newly appointed staff to achieve broader recognition and exposure at an early stage of their career

Neuchâtel, Switzerland, March 29, 2010 -- Elsevier Properties SA today announced that Reaxys® is to sponsor the Royal Australian Chemical Institute’s (RACI) 2010/11 Organic Division Lectureship for Recently Appointed Staff award.
The award is open to all RACI members who have been appointed to their first academic or industrial position within the past five years. The award winner will be given the opportunity to present a lecture in at least six Australian state capitals and/or major regional centres during the year of the lectureship.
The Organic Division of RACI established the annual lectureship to provide funding for outstanding early career organic chemists to travel around Australia and present the results of their research work.
Reaxys® is a web-based search and retrieval system for chemical compounds, bibliographic data and chemical reactions. It is owned and protected by Elsevier Properties SA and used under license.
David Evans PhD, Scientific Affairs Director at Elsevier Properties SA said today: “We are proud to provide sponsorship for this award. The Organic Division Lectureship provides a unique opportunity for chemists in the early stages of their careers. We want to celebrate their achievements and give them the recognition they deserve.”
Nominations for the 2010/11 Organic Division Lectureship award should be submitted to the Chair of the RACI Organic Division (paul.savage@csiro.au). Nominations close April 30, 2010. Details of the award can be found on the RACI web site at: http://www.raci.org.au/document/item/1381


About Elsevier Properties SA
Elsevier Properties SA is a center of excellence within Reed Elsevier for the management of intellectual property. Elsevier Properties SA owns the PharmaPendium, Beilstein and Reaxys databases. Trademarks including Reaxys®, PharmaPendium™ and The Lancet® are owned and protected by Elsevier Properties SA and used under license. For additional information see www.reedelsevier.com.

About Elsevier
Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 38,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com

Media Contact:
Tom Reller
+1 212-462-1912